Webinar: Advances in Immune-Modulating ADC Technology
Time: 10:00 AM EST, December 2, 2026
Antibody-drug conjugates (ADCs) have become an important therapeutic modality in oncology and are increasingly being explored for broader disease applications. While many approved and clinical-stage ADCs rely on cytotoxic payloads such as Topoisomerase I inhibitors or microtubule-disrupting agents, the field is now expanding toward more diverse mechanisms of action.
Immune-modulating ADCs represent a growing area of interest, offering the potential to deliver immune-stimulating or immune-suppressive payloads with improved selectivity and biological control. These approaches may help broaden the therapeutic utility of ADC technology beyond conventional cytotoxic strategies and open new opportunities in cancer, autoimmune disorders, and rare diseases.
Creative Biolabs is pleased to host an expert webinar featuring L. Nathan Tumey, Ph.D., a leading expert in ADC technology, bioconjugation, linker design, and immune-modulating payloads. In this webinar, Dr. Tumey will provide an overview of the history and current clinical status of immune-stimulating and immune-suppressive ADC designs, followed by a discussion of emerging linker technologies for immune-modulating bioconjugates.
The presentation will cover novel linker designs for both immune-stimulating and immune-suppressive conjugates, including legumain-cleavable ADC strategies, self-immolative spacers for the release of alcohol-containing payloads, and the importance of Fc-silencing for immune-modulating ADC platforms.
Why Attend?
As the ADC field matures, researchers are looking beyond classical cytotoxic payloads to develop conjugates with more nuanced biological functions. Immune-modulating ADCs may provide new ways to tune immune responses, localize therapeutic activity, and reduce systemic exposure to potent immune-active molecules.
However, successful development of these next-generation ADCs depends on careful design choices. Payload selection, linker stability, release mechanism, conjugation strategy, Fc function, and disease context can all influence therapeutic performance and safety.
This webinar will provide a focused discussion of how immune-modulating ADC designs are being developed, what differentiates immune-stimulating and immune-suppressive approaches, and how linker chemistry can shape the activity of these emerging bioconjugates.
What You Will Learn
During this webinar, you will gain insights into:
- How immune-modulating ADCs expand the therapeutic possibilities of antibody-drug conjugate technology
- The historical development and current clinical landscape of immune-stimulating and immune-suppressive ADC designs
- Why the ADC field is diversifying beyond classical Topo1 and MMAE payloads
- How linker design influences payload release, biological activity, and therapeutic performance
- The advantages and limitations of legumain-cleavable ADC designs
- How self-immolative spacers can enable the release of alcohol-containing payloads
- Why Fc-silencing is important for both immune-stimulating and immune-suppressive ADC classes
- How bioconjugation and linker-payload design can support next-generation ADC development
Who Should Attend?
This webinar is especially relevant for:
- ADC researchers working on linker-payload design, payload selection, or conjugation strategy
- Scientists developing antibody-drug conjugates for cancer, autoimmune disorders, or rare diseases
- Medicinal chemists, chemical biologists, and bioconjugation scientists focused on targeted therapeutics
- Immuno-oncology researchers exploring immune-stimulating payloads and tumor-localized immune activation
- Autoimmune and inflammatory disease researchers interested in immune-suppressive antibody conjugates
- Biotech and pharmaceutical R&D teams advancing next-generation ADC or biologic drug discovery programs
- Translational researchers evaluating how ADC design parameters influence efficacy, safety, and therapeutic window
Featured Speaker
L. Nathan Tumey, Ph.D.
Assistant Graduate Director
Vice Chair and Associate Professor
Pharmaceutical Sciences
Binghamton University
Dr. L. Nathan Tumey joined Binghamton University in 2017 after 15 years of medicinal chemistry experience in the pharmaceutical and biotechnology industry. His research focuses on the design of antibody-drug conjugates for the treatment of cancer, autoimmune disorders, and rare diseases.
Dr. Tumey is a leading expert in ADC technology, with particular expertise in bioconjugation, linker design, and immune-modulating payloads. His research includes immune-stimulating antibody conjugates, glucocorticoid-antibody conjugates, legumain-cleavable linkers, and site-specific conjugation technologies.
Before joining Binghamton University, Dr. Tumey held key leadership roles in multiple drug discovery programs, including programs focused on obesity, asthma, rheumatoid arthritis, and ADC-based cancer therapeutics. He received his doctorate in chemistry from Duke University under the supervision of Michael Pirrung and continues to advise biotechnology and pharmaceutical companies on ADC-related programs.
Download our brochure